Dr. Fuchs, the Rebecca C. Lancefield Professor of Mammalian Cell Biology and Development at Rockefeller University, has revolutionized the study of skin stem cells and their role in diseases such as cancer and inflammatory disorders. Watch as she provides an overview of the skin stem cell model and discusses current advances in our understanding of how these cells divide and differentiate.More
Integration-free technologies with high reprogramming efficiency are key to the use of induced pluripotent stem cells and their derivatives in cell therapy and drug discovery applications. Sendai virus (SeV) has been used to reprogram somatic cells with high efficiency however, while recombinant SeV vectors only replicate in the cytoplasm of infected cells, continued cytoplasmic replication after reprogramming could prevent the use of SeV in therapeutic applications. Ban et al. present the use of temperature sensitive SeV vectors to generate viral and reprogramming factor free iPSCs from human fibroblasts and CD34+ cord blood cells at high efficiency. More
Two recent papers report successful and consistent gene targeting in ESC and iPSC. The methods described overcome the current issue of exogeneous DNA introduced in gene therapy. This progresses the field a step closer to therapeutic use of functional cells derived from ex-vivo repaired ES and iPS cells.
The end of the year is a great time to reflect on the events of the year and predict what might happen next year. I’ve asked Dr. Uma Lakshmipathy, Principle Scientist with Life Technologies, to tell us about her work with stem cells at Life Technologies, her thoughts on the biggest discoveries in stem cell research in 2011 and prospects for 2012. More
In the last decade, miRNAs have been established as one of the primary modulators of biological pathways owing to their ability to impact possibly >30% of all protein-coding genes. Their role as central regulators of stem cell maintenance and differentiation is becoming more prominent in the last two years. More